Review demonstrates that fecal microbiota transplantation alleviates refractory urticaria by restoring gut barrier function, indicating a novel gut-skin therapeutic strategy.
Key Points
To review the mechanisms, clinical relevance, and therapeutic potential of fecal microbiota transplantation (FMT) for refractory urticaria via the gut-skin axis.
Synthesized recent mechanistic and clinical literature addressing the gut-skin axis in urticaria pathogenesis.
Evaluated clinical data on FMT interventions targeting gut dysbiosis, mast cell activation, and gut barrier integrity.
Gut microbiota dysbiosis drives urticaria pathogenesis through dysregulated immune responses and heightened mast cell activation.
Preliminary clinical findings show FMT alleviates urticaria symptoms and restores compromised intestinal barrier function.
Standardized treatment protocols and further clinical trials are required to establish long-term safety and efficacy.